Trials / Terminated
TerminatedNCT01501383
A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy With a 24-Week Open-Label Extension
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 55 (actual)
- Sponsor
- Vertex Pharmaceuticals Incorporated · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of VX-765 in subjects with treatment-resistant partial epilepsy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VX-765 Part A | Tablets of VX-765 given at different doses based on treatment group in Part A |
| DRUG | Placebo | Matching placebo |
| DRUG | VX-765 Part B | Tablets of VX-765 given at different doses based on patients who meet the study eligibility criteria for Part B |
Timeline
- Start date
- 2011-12-01
- Primary completion
- 2013-08-01
- First posted
- 2011-12-29
- Last updated
- 2020-09-30
Locations
24 sites across 2 countries: United States, Germany
Source: ClinicalTrials.gov record NCT01501383. Inclusion in this directory is not an endorsement.